Medication adherence after myocardial infarction: A long way left to go

Journal of General Internal Medicine

Volumn 23, Issue 2, 2008, Pages 216-218

  Choudhry, Niteesh K ^a   Winkelmayer, Wolfgang C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; EDITORIAL; FAMILY COUNSELING; HEALTH CARE COST; HEALTH CARE QUALITY; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; ISCHEMIC HEART DISEASE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; SUPPORT GROUP; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; RECURRENCE;

EID: 39149123172     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0478-8     Document Type: Editorial

References (25)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-53.
2. Yach D, Leeder S, Bell J, Kistnasamy B. Global chronic diseases. Science. 2005;307(5708):317.
3. American Heart Association. Heart Disease and Stroke Statistics-2006 Uptake. Dallas: American Heart Association; 2004.
4. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:E1-E211.
5. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.
6. Bradley EH, Holmboe ES, Mattera JA, Roumanis SA, Radford MJ, Krumholz HM. A qualitative study of increasing beta-blocker use after myocardial infarction: Why do some hospitals succeed? JAMA. 2001;285:2604-11.
7. American Heart Association. Get With The Guidelines. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3045578. Accessed July 10, 2007.
8. Rogers AM, Ramanath VS, Grzybowski M, et al. The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: The American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan. Am Heart J. 2007;154:461-9.
9. Williams SC, Schmaltz SP, Morton DJ, Koss RG, Loeb JM. Quality of care in U.S. hospitals as reflected by standardized measures, 2002-2004. N Engl J Med. 2005;353:255-64.
10. [No authors listed] A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247(12):1707-1714 (Mar 26).
11. Lee TH. Eulogy for a quality measure. N Engl J Med. 2007;357:1175-7.
12. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42:200-9.
13. Ackincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to evidence-based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med. 2008 (in press). DOI 10.1007/s11606-007-0351-9.
14. World Health Organization. Adherence to long-term therapies: Evidence for action. Available at: www.who.int/chronic_conditions/en/adherence_report.pdf. Accessed January 6, 2006.
15. Kramer JM, Hammill B, Anstrom PJ, et al. National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152:454.e451-454. e458.
16. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-61.
17. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203-12.
18. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88:229-33.
19. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842-7.
20. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-86.
21. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331-6.
22. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97.
23. Sokol MC, McGuigan KA, Verbrugge R, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-30.
24. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-9.
25. Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. The cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2007 (in press).